Drug-eluting stents for the prevention of restenosis: In quest for the holy grail
- 21 February 2002
- journal article
- review article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 55 (3), 409-417
- https://doi.org/10.1002/ccd.10161
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Percutaneous Coronary Intervention in the Current Era Compared With 1985–1986Circulation, 2000
- Angiographic Patterns of In-Stent RestenosisCirculation, 1999
- Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell CycleCirculation, 1999
- A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1999
- In-Stent Restenosis: Contributions of Inflammatory Responses and Arterial Injury to Neointimal HyperplasiaJournal of the American College of Cardiology, 1998
- Rapamycin inhibits vascular smooth muscle cell migration.Journal of Clinical Investigation, 1996
- Patterns and Mechanisms of In-Stent RestenosisCirculation, 1996
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle CellsCirculation Research, 1995
- RAPAMYCIN INHIBITS ARTERIAL INTIMAL THICKENING CAUSED BY BOTH ALLOIMMUNE AND MECHANICAL INJURYTransplantation, 1993